A number of other research analysts have also recently commented on VRTX. BidaskClub cut Vertex Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, April 16th. Zacks Investment Research cut Vertex Pharmaceuticals from a hold rating to a strong sell rating in a research note on Friday, March 8th. Evercore ISI began coverage on Vertex Pharmaceuticals in a research note on Thursday, April 11th. They set an in-line rating and a $183.00 price target on the stock. Svb Leerink restated a market perform rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, March 19th. Finally, BMO Capital Markets upped their price target on Vertex Pharmaceuticals to $234.00 and gave the stock an outperform rating in a research note on Wednesday, February 6th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $203.31.
NASDAQ:VRTX opened at $168.16 on Thursday. Vertex Pharmaceuticals has a 52 week low of $144.07 and a 52 week high of $195.81. The firm has a market cap of $42.99 billion, a price-to-earnings ratio of 59.42, a PEG ratio of 2.43 and a beta of 1.64.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Tuesday, February 5th. The pharmaceutical company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.24. Vertex Pharmaceuticals had a return on equity of 24.15% and a net margin of 68.81%. The company had revenue of $870.11 million for the quarter, compared to analysts’ expectations of $818.29 million. During the same period in the prior year, the firm earned $0.61 earnings per share. The firm’s revenue was up 33.5% compared to the same quarter last year. Sell-side analysts predict that Vertex Pharmaceuticals will post 2.97 EPS for the current fiscal year.
In other news, EVP David Altshuler sold 2,125 shares of the stock in a transaction on Tuesday, January 22nd. The stock was sold at an average price of $193.48, for a total value of $411,145.00. Following the sale, the executive vice president now directly owns 41,238 shares in the company, valued at $7,978,728.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Paul M. Silva sold 1,289 shares of the stock in a transaction on Wednesday, February 6th. The shares were sold at an average price of $193.00, for a total value of $248,777.00. Following the completion of the sale, the senior vice president now owns 13,938 shares in the company, valued at $2,690,034. The disclosure for this sale can be found here. Over the last quarter, insiders sold 210,018 shares of company stock worth $38,398,113. Insiders own 0.75% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in VRTX. Oregon Public Employees Retirement Fund raised its stake in shares of Vertex Pharmaceuticals by 16,530.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,610,881 shares of the pharmaceutical company’s stock valued at $28,000 after acquiring an additional 4,583,156 shares in the last quarter. FMR LLC raised its stake in shares of Vertex Pharmaceuticals by 13.3% in the fourth quarter. FMR LLC now owns 20,483,109 shares of the pharmaceutical company’s stock valued at $3,394,256,000 after acquiring an additional 2,411,631 shares in the last quarter. Norges Bank purchased a new position in Vertex Pharmaceuticals in the fourth quarter valued at $380,584,000. Jennison Associates LLC increased its holdings in Vertex Pharmaceuticals by 11.9% in the fourth quarter. Jennison Associates LLC now owns 6,941,621 shares of the pharmaceutical company’s stock valued at $1,150,296,000 after buying an additional 739,128 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its holdings in Vertex Pharmaceuticals by 74.9% in the fourth quarter. Thrivent Financial for Lutherans now owns 601,559 shares of the pharmaceutical company’s stock valued at $99,685,000 after buying an additional 257,683 shares during the last quarter. Institutional investors and hedge funds own 95.37% of the company’s stock.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.